<DOC>
	<DOC>NCT00963742</DOC>
	<brief_summary>The objectives of this multi-center clinical investigation are to determine the safety and effectiveness of the Lenstec Softec HD Posterior Chamber intraocular lens (IOL) following one year of post-operative assessment.</brief_summary>
	<brief_title>Lenstec Softec HD Posterior Chamber Intraocular Lens Clinical Investigational Protocol</brief_title>
	<detailed_description>The Softec HD Posterior Chamber IOL is designed for the treatment of aphakia. The lens is indicated for primary implantation when a cataractous lens has been removed by phacoemulsification with circular tear capsulotomy and the posterior capsule intact. The intended benefit of the Softec HD Posterior Chamber IOL is to provide enhanced vision.</detailed_description>
	<mesh_term>Cataract</mesh_term>
	<criteria>Cataract requiring cataract extraction Study IOL to only be implanted in 1 eye Distance BCVA 20/40 or worse or glare acuity worse than 20/30 Ability to comply with study followup requirements Patients with serious corneal disease, previous surgery or serious systemic disease Ocular condition that could impact vision after cataract surgery Pregnant or lactating women Use of ocular or systemic medications that could impact vision</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>cataract surgery</keyword>
	<keyword>IOL</keyword>
	<keyword>Intraocular lens</keyword>
</DOC>